Anna Ljung
Chief Executive Officer bij MOBERG PHARMA AB
Vermogen: 1 055 $ op 29-02-2024
Profiel
Anna Ljung occupies the position of Chief Executive Officer at Moberg Pharma AB and Chairman for Moberg Derma Incentives AB (a subsidiary of Moberg Pharma AB).
She is also on the board of ADDvise Group AB, Saniona AB and Saniona A.
In her past career she occupied the position of Chairman at OncoZenge AB, Chief Financial Officer of Athera Biotechnologies AB and Chief Financial Officer for Lipopetide AB.
She received a graduate degree from Stockholm School of Economics.
Bekende belangen in openbare bedrijven
Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
---|---|---|---|---|
SANIONA AB
0.00% | 31-12-2022 | 5 471 ( 0.00% ) | 1 055 $ | 29-02-2024 |
Actieve functies van Anna Ljung
Bedrijven | Functie | Begin |
---|---|---|
MOBERG PHARMA AB | Chief Executive Officer | 15-05-2019 |
SANA AB | Director/Board Member | 19-01-2018 |
ADDVISE GROUP AB | Director/Board Member | 01-01-2022 |
Saniona A/S
Saniona A/S Miscellaneous Commercial ServicesCommercial Services Part of Saniona AB, Saniona A/S is a Danish company dedicated to improving the lives of rare disease patients worldwide through scientific innovation. The private company focuses on Prader-Willi Syndrome, a rare genetic disorder characterized by insatiable appetite, abnormal growth and body composition, low muscle tone, and social/emotional/cognitive deficits. Saniona is a leader in the discovery of highly specific ion channel modulators, which is a validated approach to treating diseases such as diabetes, hypertension, and epilepsy. The company's robust ion channel drug discovery engine has led to the development of San711, a first-in-class positive allosteric modulator of GABAA ?3 receptors, and San903, a potential first-in-class inhibitor of the calcium-activated potassium ion channel, KCA3.1, both of which are in development for rare neuropathic, inflammatory, and fibrotic disorders. | Director/Board Member | - |
Moberg Derma Incentives AB | Chairman | - |
Eerdere bekende functies van Anna Ljung
Bedrijven | Functie | Einde |
---|---|---|
ONCOZENGE AB | Chairman | 21-08-2023 |
Athera Biotechnologies AB
Athera Biotechnologies AB Pharmaceuticals: MajorHealth Technology Athera Biotechnologies AB operates as a biopharmaceutical company which focuses on developing targeted anti-inflammatory biological candidate drugs and companion diagnostics. It has a proprietary program the fully human antibody PC-mAb. The frim develops a biomarker and companion diagnostic CVDefine® kit. Its PC-mAb is a fully human monoclonal antibody which neutralizes a key driver of vascular inflammation, phosphorylcholine, which targets market of reducing secondary cardiovascular events, focusing on high-risk patients with low anti-PC levels. The company was founded by Johan Frostegard in 2002 and is headquartered in Stockholm, Sweden. | Director of Finance/CFO | 01-01-2006 |
Lipopetide AB | Director of Finance/CFO | 01-01-2006 |
Advantice Health LLC (New Jersey)
Advantice Health LLC (New Jersey) Medical DistributorsDistribution Services Advantice Health LLC manufactures and supplies therapeutic medicines and personal products. It is engaged in the marketing, sale and distribution of over-the-counter (OTC) medicines to drug stores, food stores, mass merchandisers, health professionals and international markets. It is best known for podiatrist recommended Kerasal One-Step Exfoliating Moisturizer Therapy. The company was founded in 2004 and is headquartered in Cedar Knolls, NJ. | Director/Board Member | - |
░░░ ░░░ ░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - |
Opleiding van Anna Ljung
Stockholm School of Economics | Graduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 4 |
---|---|
ADDVISE GROUP AB | Distribution Services |
MOBERG PHARMA AB | Health Technology |
SANA AB | Health Technology |
ONCOZENGE AB | Health Technology |
Bedrijven in privébezit | 6 |
---|---|
Athera Biotechnologies AB
Athera Biotechnologies AB Pharmaceuticals: MajorHealth Technology Athera Biotechnologies AB operates as a biopharmaceutical company which focuses on developing targeted anti-inflammatory biological candidate drugs and companion diagnostics. It has a proprietary program the fully human antibody PC-mAb. The frim develops a biomarker and companion diagnostic CVDefine® kit. Its PC-mAb is a fully human monoclonal antibody which neutralizes a key driver of vascular inflammation, phosphorylcholine, which targets market of reducing secondary cardiovascular events, focusing on high-risk patients with low anti-PC levels. The company was founded by Johan Frostegard in 2002 and is headquartered in Stockholm, Sweden. | Health Technology |
Advantice Health LLC (New Jersey)
Advantice Health LLC (New Jersey) Medical DistributorsDistribution Services Advantice Health LLC manufactures and supplies therapeutic medicines and personal products. It is engaged in the marketing, sale and distribution of over-the-counter (OTC) medicines to drug stores, food stores, mass merchandisers, health professionals and international markets. It is best known for podiatrist recommended Kerasal One-Step Exfoliating Moisturizer Therapy. The company was founded in 2004 and is headquartered in Cedar Knolls, NJ. | Distribution Services |
Saniona A/S
Saniona A/S Miscellaneous Commercial ServicesCommercial Services Part of Saniona AB, Saniona A/S is a Danish company dedicated to improving the lives of rare disease patients worldwide through scientific innovation. The private company focuses on Prader-Willi Syndrome, a rare genetic disorder characterized by insatiable appetite, abnormal growth and body composition, low muscle tone, and social/emotional/cognitive deficits. Saniona is a leader in the discovery of highly specific ion channel modulators, which is a validated approach to treating diseases such as diabetes, hypertension, and epilepsy. The company's robust ion channel drug discovery engine has led to the development of San711, a first-in-class positive allosteric modulator of GABAA ?3 receptors, and San903, a potential first-in-class inhibitor of the calcium-activated potassium ion channel, KCA3.1, both of which are in development for rare neuropathic, inflammatory, and fibrotic disorders. | Commercial Services |
Lipopetide AB | |
Mpj Otc AB
Mpj Otc AB Pharmaceuticals: OtherHealth Technology Part of Moberg Pharma AB, Mpj Otc AB is a private company that manufactures and distributes therapeutic medicines and personal products. | Health Technology |
Moberg Derma Incentives AB |